Taltz Injection, Solution
NDC Package 0002-7724-11
Package Information
Taltz (ixekizumab) injection is a medication used to treat plaque psoriasis and certain types of arthritis (psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis). This formulation utilizes a injection, solution delivery system. Marketed by Eli Lilly And Company, this product is identified by NDC 0002-7724 and is authorized under FDA application BLA125521.
Identification & Billing
- RxCUI: 1745103 - ixekizumab 80 MG in 1 ML Auto-Injector
- RxCUI: 1745103 - 1 ML ixekizumab 80 MG/ML Auto-Injector
- RxCUI: 1745103 - ixekizumab 80 MG per 1 ML Auto-Injector
- RxCUI: 1745108 - taltz 80 MG in 1 ML Auto-Injector
- RxCUI: 1745108 - 1 ML ixekizumab 80 MG/ML Auto-Injector [Taltz]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0002 - Eli Lilly And Company
- 0002-7724 - Taltz
- 0002-7724-11 - 1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE (0002-7724-01)
- 0002-7724 - Taltz
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0002-7724). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0002-7724-11 identifies a specific commercial package of 1 syringe in 1 carton / 1 ml in 1 syringe (0002-7724-01) of Taltz, a human prescription drug labeled by Eli Lilly And Company. This injection, solution is formulated for subcutaneous use and contains ixekizumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eli Lilly And Company on March 22, 2016. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat plaque psoriasis and certain types of arthritis (psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis). Ixekizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-17A) that may cause inflammation and swelling.
How is this Eli Lilly And Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002772411. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.